Lentivirus is a genus of slow viruses of the Retroviridae family, characterized by a long incubation period.
In this interview, we speak with Laralynne Przybyla about how she is utilizing CRISPR platforms to understand human disease biology in greater detail.
Astrea Bioseparations (“Astrea Bio”), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO™ lentiviral vector (LVV) purification technology.
VectorBuilder Inc. has announced the construction of a new R&D and manufacturing center in Guangzhou, China.
AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2.
Global provider of human and animal biospecimens - AMSBIO offers a custom procurement service enabling researchers to source specific biofluid and tissue samples which are not already available in their extensive biorepository.
AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.
Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.
AMSBIO have supplied custom lentivectors to Francesco Pampaloni and his team at the Buchmann Institute for Molecular Life Sciences in Frankfurt, Germany allowing them to visualize cell nuclei and F-actin cytoskeleton in their organoids.